Engineering CAR T Cells to Deliver Endogenous RNA Wakes Solid Tumors to Respond to Therapy

A new study from Penn Medicine demonstrates a naturally occurring RNA can activate the body’s own natural T cells to seek out cancer cells that may have escaped recognition by CAR T cells.

Article from Penn Medicine

September 2nd, 2021|Cell and Gene Therapy, Innovation, Regional News Roundup|Comments Off on Engineering CAR T Cells to Deliver Endogenous RNA Wakes Solid Tumors to Respond to Therapy

Renovacor, Inc. Closes Its Business Combination with Chardan Healthcare Acquisition 2 Corp. and Will Begin Trading on the New York Stock Exchange

Renovacor, Inc. will begin trading on the New York Stock Exchange under ticket symbols “RCOR” and “RCOR.WS”, respectively.

Article from Business Wire

September 2nd, 2021|Cell and Gene Therapy, Innovation, Regional News Roundup|Comments Off on Renovacor, Inc. Closes Its Business Combination with Chardan Healthcare Acquisition 2 Corp. and Will Begin Trading on the New York Stock Exchange

XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina

A clinical-stage biopharmaceutical company has announced the completion of a new development.

Article from Business Wire

July 27th, 2021|Cell and Gene Therapy, Innovation, Regional News Roundup|Comments Off on XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina

Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn’s Disease Patients

A biopharmaceutical company announced the results of a Phase 1b of CERC-002.

Article from GlobeNewswire

July 26th, 2021|Cell and Gene Therapy, Innovation, Regional News Roundup|Comments Off on Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn’s Disease Patients

Multimillion-dollar project looks to transform Philadelphia into a hotbed for minority-owned businesses

Philadelphia, alongside other local stakeholder, has issued recommendations for fostering diversity in its business community.

Article from Philadelphia Business Journal

July 21st, 2021|Cell and Gene Therapy, Investments, Real Estate, Regional News Roundup|Comments Off on Multimillion-dollar project looks to transform Philadelphia into a hotbed for minority-owned businesses

Spark Therapeutics’ SPK-8011 Suggests Stable and Durable Factor VIII Expression in Largest Phase 1/2 Gene Therapy Study in Hemophilia A to Date

Member of the Roche Groupe, Spark Therapeutics, announced their updated data to challenge the inevitability of genetic disease.

Article from Spark Therapeutics

July 21st, 2021|Cell and Gene Therapy, Innovation, Regional News Roundup|Comments Off on Spark Therapeutics’ SPK-8011 Suggests Stable and Durable Factor VIII Expression in Largest Phase 1/2 Gene Therapy Study in Hemophilia A to Date

Gene therapy developer Passage Bio adds a trio to its C-suite

Spun out of the University of Pennsylvania, Philadelphia gene therapy developer has added Maria Törnsén, Simona King, and Dr. Mark Forman to their executive C-suite.

Article from Philadelphia Business Journal

July 19th, 2021|Cell and Gene Therapy, Regional News Roundup, Talent Announcements|Comments Off on Gene therapy developer Passage Bio adds a trio to its C-suite

Development team behind $2.6B Navy Yard project makes ‘unparalleled’ diversity, equity and inclusion pledge

The development team behind the new Navy Yard project has firmed up a program for the project which includes directing $1 billion into initiatives surrounding diversity, equity, and inclusion.

Article from Philadelphia Business Journal

July 13th, 2021|Cell and Gene Therapy, Corporate Culture, Regional News Roundup|Comments Off on Development team behind $2.6B Navy Yard project makes ‘unparalleled’ diversity, equity and inclusion pledge

Thomas Jefferson University appoints first chairwoman in 197-year history

For the first time in its 197-year history, newly elected board chair, Patricia D. Wellenbach will be the first woman to lead Thomas Jefferson University’s Board of Trustees.

Article from Philadelphia Business Journal

 

July 7th, 2021|Cell and Gene Therapy, Corporate Culture, Regional News Roundup, Talent Announcements|Comments Off on Thomas Jefferson University appoints first chairwoman in 197-year history
Go to Top